David L. Saunders, Benjamin C. Pierson, Oksana Zlenko, H. C. Gelhaus
{"title":"Considerations for prevention of and emergency response to tularemia outbreaks in Ukraine: vaccine involvement","authors":"David L. Saunders, Benjamin C. Pierson, Oksana Zlenko, H. C. Gelhaus","doi":"10.3389/fbrio.2024.1364708","DOIUrl":"https://doi.org/10.3389/fbrio.2024.1364708","url":null,"abstract":"Tularemia is a highly dangerous, febrile zoonotic bacterial infection, endemic to many regions of the Northern hemisphere including Eastern Europe. The current war in Ukraine raises the risk for both natural outbreaks of tularemia resulting from destroyed infrastructure, and potential use as a weapon of war or bioterrorism. There has been a substantial history of outbreaks in prior wars in the region, and tularemia has been previously weaponized and stockpiled as an offensive agent. There are current reports of “mouse fever”, where Russian soldiers are affected with a high fever associated with mice in the battlefield. While antibiotic countermeasures to naturally occurring forms of tularemia are available, these may not be appropriate for long-term risks on the battlefield and could contribute to antibiotic resistance. At this time, there are no FDA or EMA approved tularemia vaccines, which are an ideal alternative to antibiotic prophylaxis. Vaccines have advantages in not requiring diagnosis, are generally safe and effective, leading to long-lasting prophylaxis with little impact to the patient and little need for future medical intervention. The potential for engineered forms of the disease for deliberate use may limit the effectiveness of existing countermeasures. The sporadic nature of outbreaks, and likely outcomes following deliberate use raise a number of complexities in a potential emergency response. Means to optimize potential countermeasure assessment, including responsible and effective vaccine candidate testing are discussed.","PeriodicalId":472148,"journal":{"name":"Frontiers in Bacteriology","volume":"13 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139869349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
David L. Saunders, Benjamin C. Pierson, Oksana Zlenko, H. C. Gelhaus
{"title":"Considerations for prevention of and emergency response to tularemia outbreaks in Ukraine: vaccine involvement","authors":"David L. Saunders, Benjamin C. Pierson, Oksana Zlenko, H. C. Gelhaus","doi":"10.3389/fbrio.2024.1364708","DOIUrl":"https://doi.org/10.3389/fbrio.2024.1364708","url":null,"abstract":"Tularemia is a highly dangerous, febrile zoonotic bacterial infection, endemic to many regions of the Northern hemisphere including Eastern Europe. The current war in Ukraine raises the risk for both natural outbreaks of tularemia resulting from destroyed infrastructure, and potential use as a weapon of war or bioterrorism. There has been a substantial history of outbreaks in prior wars in the region, and tularemia has been previously weaponized and stockpiled as an offensive agent. There are current reports of “mouse fever”, where Russian soldiers are affected with a high fever associated with mice in the battlefield. While antibiotic countermeasures to naturally occurring forms of tularemia are available, these may not be appropriate for long-term risks on the battlefield and could contribute to antibiotic resistance. At this time, there are no FDA or EMA approved tularemia vaccines, which are an ideal alternative to antibiotic prophylaxis. Vaccines have advantages in not requiring diagnosis, are generally safe and effective, leading to long-lasting prophylaxis with little impact to the patient and little need for future medical intervention. The potential for engineered forms of the disease for deliberate use may limit the effectiveness of existing countermeasures. The sporadic nature of outbreaks, and likely outcomes following deliberate use raise a number of complexities in a potential emergency response. Means to optimize potential countermeasure assessment, including responsible and effective vaccine candidate testing are discussed.","PeriodicalId":472148,"journal":{"name":"Frontiers in Bacteriology","volume":"15 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139809394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mohamed Halawa, Maxwell Akantibila, Briana E. Reid, Valerie J. Carabetta
{"title":"Therapeutic proteins have the potential to become new weapons in the fight against antibiotic resistance","authors":"Mohamed Halawa, Maxwell Akantibila, Briana E. Reid, Valerie J. Carabetta","doi":"10.3389/fbrio.2023.1304444","DOIUrl":"https://doi.org/10.3389/fbrio.2023.1304444","url":null,"abstract":"Humans are continually challenged to find new strategies to fight bacterial diseases due to the global health threat of antibiotic resistance. Conventional antibiotics, once hailed as miracle treatments, are progressively losing their effectiveness as drug-resistant bacteria continue to emerge, including multidrug-resistant (MDR) strains. An attractive approach to solving the antibiotic resistance problem is the investigation of other methods, such as therapeutic proteins. Here, we begin with a discussion of antimicrobial resistance and common strategies that bacteria employ to become resistant. Next, we discuss the potential use of antimicrobial peptides and monoclonal antibodies, two types of therapeutic proteins, as possible antimicrobial therapeutics. We discuss their structure, mechanism of action, and highlight examples of possible candidate molecules for clinical use. Finally, we discuss the remaining challenges and explore potential solutions for the implementation of therapeutic proteins into practical clinical use.","PeriodicalId":472148,"journal":{"name":"Frontiers in Bacteriology","volume":"3 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139007726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Christopher P. Klimko, Kay B. Barnes, Nathaniel O. Rill, Jennifer L. Shoe, Jennifer L. Dankmeyer, Melissa Hunter, Susan L. Welkos, David DeShazer, Sergei S. Biryukov, Sarah V. Harding, Christopher K. Cote
{"title":"Detection of low-level animal-to-animal transmission in BALB/c mouse models of melioidosis","authors":"Christopher P. Klimko, Kay B. Barnes, Nathaniel O. Rill, Jennifer L. Shoe, Jennifer L. Dankmeyer, Melissa Hunter, Susan L. Welkos, David DeShazer, Sergei S. Biryukov, Sarah V. Harding, Christopher K. Cote","doi":"10.3389/fbrio.2023.1303051","DOIUrl":"https://doi.org/10.3389/fbrio.2023.1303051","url":null,"abstract":"Burkholderia pseudomallei , the causative agent of melioidosis, has two phases of infection. The acute phase occurs shortly after infection and is associated with bacterial sepsis, potentially leading to death, whilst the chronic phase occurs when infection persists for longer periods or is asymptomatic for months or years. BALB/c mice are more susceptible to melioidosis compared to C57BL/6 mice and are routinely models for the acute phase of infection. However, in some instances when medical countermeasures are being evaluated, mice continue to succumb to disease throughout the course of the experimental infection. Whilst B. pseudomallei is not known to be transmitted from mouse-to-mouse, we hypothesized that mice that have recovered from infection after medical countermeasure intervention may become reinfected from chronically infected mice. We tested this hypothesis by cohousing naïve mice with mice exposed to B. pseudomallei by the inhalational or intraperitoneal routes in either static or ventilated caging. Mice that were exposed to aerosolized B. pseudomallei transmitted the bacterium to approximately 4% of their naïve cagemates, whereas mice that were infected by the intraperitoneal route transmitted to approximately 8% of their naïve cagemates. Whilst the exact route of transmission remains to be determined, the results of this study showed that low levels of mouse-to-mouse transmission of B. pseudomallei are possible. We conclude that although the chance of reinfection is low amongst mice housed in the same cage, this possible scenario should be considered when interpreting data from the BALB/c mouse model of melioidosis in lengthy studies.","PeriodicalId":472148,"journal":{"name":"Frontiers in Bacteriology","volume":"18 19‐20","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135589511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kartik Kumar Rathi, Nimrata Kumari, Muhammad Daniyal Javaid, Umair Saleem, Eric Mortensen, Yanjiao Zhou, Narinder Maheshwari
{"title":"Gut microbiome and prediabetes - a review","authors":"Kartik Kumar Rathi, Nimrata Kumari, Muhammad Daniyal Javaid, Umair Saleem, Eric Mortensen, Yanjiao Zhou, Narinder Maheshwari","doi":"10.3389/fbrio.2023.1242297","DOIUrl":"https://doi.org/10.3389/fbrio.2023.1242297","url":null,"abstract":"While there is extensive information available on how the gut microbiota alters in composition between normal individuals and individuals with diabetes, there is little evidence available on whether the alterations become apparent at the prediabetes stage (a preliminary state to T2DM which is characterized by altered glycemic parameters relative to a normal euglycemic state), and if these variations are potentially linked with the progression from prediabetes into diabetes. In this review, we aim to summarize all the findings on compositional shifts in the gut microbiome that are shown to occur in individuals with prediabetes and diabetes in contrast to euglycemic states. Our review also highlights the potential pathophysiological mechanisms that could explain these alterations in metabolism due to the presence of varying microbial environments in the gut. Moreover, we also gather the available evidence on the role played by various factors, such as dietary changes and exercise, and their potential role in inducing a change in the gut microbiome. Last but not least, our review also assess the changes to the microbiota population brought about by a subsequent probiotic and symbiotic supplementation, Metformin and Acarbose. Additionally, we also evaluate the use of above mentioned interventions in mitigating the progression of prediabetes into subsequent diabetes mellitus. We believe this review can help understand the dynamic role played by the gut microbiome in the onset of prediabetes and if there is a possibility of reverting back to euglycemia with correct measures.","PeriodicalId":472148,"journal":{"name":"Frontiers in Bacteriology","volume":"37 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135968878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jana Schwarzerova, Anastasiya Labanava, Ivan Rychlik, Margaret Varga, Darina Cejkova
{"title":"A minireview on the bioinformatics analysis of mobile gene elements in microbiome research","authors":"Jana Schwarzerova, Anastasiya Labanava, Ivan Rychlik, Margaret Varga, Darina Cejkova","doi":"10.3389/fbrio.2023.1275910","DOIUrl":"https://doi.org/10.3389/fbrio.2023.1275910","url":null,"abstract":"The horizontal transfer of mobile gene elements between bacteria plays a crucial role in their evolutionary dynamics. Additionally, it enables the accumulation and dissemination of genes conferring antibiotic and heavy-metal resistance, and thus contributes to the worldwide emergence and spread of drug-resistance pathogens. This process is instrumental in maintaining genetic diversity within bacterial populations and facilitates their adaptation to novel environments. It allows bacteria to acquire genes responsible for the synthesis of enzymes that utilize alternative energy sources and substrates. Furthermore, bacteria can acquire genes associated with toxin production and increased virulence. Horizontal gene transfer serves as a pivotal mechanism in bacterial evolution, enabling the acquisition of novel genetic information and enhancing their capabilities. However, the proper detection and identification of horizontally transferred genes at the microbiome scale is challenging, whether using wet-lab experiments or bioinformatics approaches. In the paper, we summarize current bioinformatics tools for detecting Horizontal Gene Transfer and present the results of our bioinformatic analysis on a collection of genomes originating from chicken gut microbiota.","PeriodicalId":472148,"journal":{"name":"Frontiers in Bacteriology","volume":"57 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136254187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Artificial intelligence in accelerating vaccine development - current and future perspectives","authors":"Rahul Kaushik, Ravi Kant, Myron Christodoulides","doi":"10.3389/fbrio.2023.1258159","DOIUrl":"https://doi.org/10.3389/fbrio.2023.1258159","url":null,"abstract":"Tackling antimicrobial resistance requires the development of new drugs and vaccines. Artificial intelligence (AI) assisted computational approaches offer an alternative to the traditionally empirical drug and vaccine discovery pipelines. In this mini review, we focus on the increasingly important role that AI now plays in the development of vaccines and provide the reader with the methods used to identify candidate vaccine candidates for selected multi-drug resistant bacteria.","PeriodicalId":472148,"journal":{"name":"Frontiers in Bacteriology","volume":"158 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135095698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sergei S. Biryukov, Christopher P. Klimko, Jennifer L. Dankmeyer, Ronald G. Toothman, Jennifer L. Shoe, Melissa Hunter, Nathaniel O. Rill, Yuli Talyansky, Michael L. Davies, Ju Qiu, David P. Fetterer, Joel A. Bozue, Susan L. Welkos, Christopher K. Cote
{"title":"Live attenuated vaccines and layered defense strategies to combat infections caused by nonencapsulated Yersinia pestis","authors":"Sergei S. Biryukov, Christopher P. Klimko, Jennifer L. Dankmeyer, Ronald G. Toothman, Jennifer L. Shoe, Melissa Hunter, Nathaniel O. Rill, Yuli Talyansky, Michael L. Davies, Ju Qiu, David P. Fetterer, Joel A. Bozue, Susan L. Welkos, Christopher K. Cote","doi":"10.3389/fbrio.2023.1240698","DOIUrl":"https://doi.org/10.3389/fbrio.2023.1240698","url":null,"abstract":"Introduction Plague is an ancient disease caused by Yersinia pestis , a widely disseminated Tier 1 pathogen that poses significant public health and biothreat risks. The rapid course and high mortality of pneumonic plague limit the efficacy of antibiotic treatment and mandate the need for an effective, licensed, and readily available vaccine. New candidate vaccines are being developed; however, their efficacy in nonhuman primates, optimal vaccination schedule and immune response, duration of protection, and breadth of coverage against various virulent strains are inadequately understood. In the current work, we explored homologous and heterologous vaccination schemes using the sensitive BALB/c mouse models of bubonic and pneumonic plague challenged with Y. pestis strain C12. This strain, a derivative of the wild-type strain CO92, lacks the anti-phagocytic F1 capsule yet remains highly virulent. Protection against such nonencapsulated strains has been particularly elusive. Methods We tested the efficacy of live attenuated vaccine (LAV) derivatives of Y. pestis CO92 or C12 with a deletion of a type 3 secretion-associated gene (Δ yscN ) or the pgm pigmentation locus, and they were cured of the pPst (PCP1) plasmid (CO92 pgm − pPst − ). The LAVs were evaluated alone or accompanied by a dose of a protein subunit vaccine (rF1V or rV). Results The most protective and immunogenic vaccination scheme, as tested under a variety of conditions in bubonic and pneumonic plague models, was heterologous vaccination with a LAV and the recombinant rF1V or rV protein subunit vaccine. Furthermore, in the heterologous scheme, different LAVs and subunit vaccines could be substituted, affording flexibility in vaccine component selection. We also evaluated a novel intervention strategy consisting of vaccination and post-exposure antibiotic treatment. The layering of vaccination with the LAVs and post-exposure treatment with streptomycin was synergistic, extending the time after the Y. pestis C12 challenge when treatment remained effective and affording a sparing of antibiotics. Conclusion The current work defined effective and flexible vaccination and treatment interventions that successfully prevented lethal infection with virulent, nonencapsulated Y. pestis .","PeriodicalId":472148,"journal":{"name":"Frontiers in Bacteriology","volume":"54 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136059338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}